Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400753 | 0.92 | ALDH1A1 (0.44) | CYP3A4GAAALDH1A1HPGDHTT | |
| SCHEMBL11498378 | 0.85 | GAA (0.36) | CYP3A4GAANPSR1ALDH1A1HPGD | |
| SCHEMBL6401720 | 0.81 | ALDH1A1 (0.44) | CYP3A4GAAALDH1A1HPGDHTT | |
| SCHEMBL976299 | 0.74 | ALDH1A1 (0.39) | NPSR1ALDH1A1HPGDHTTLMNA | |
| SCHEMBL146503 | 0.71 | CYP1A2 (0.56) | CYP3A4GAAALDH1A1HPGDHTT | |
| SCHEMBL973713 | 0.71 | HPGD (0.37) | GAAALDH1A1HPGDHTTLMNA | |
| SCHEMBL6401477 | 0.69 | KMT2A (0.39) | MAPTMEN1KMT2A | |
| SCHEMBL975310 | 0.68 | PGR (0.44) | GAAALDH1A1HPGDLMNAALPL | |
| SCHEMBL13730929 | 0.67 | CYP1A2 (0.36) | — | |
| SCHEMBL9776455 | 0.67 | ALDH1A1 (0.55) | NPSR1ALDH1A1HPGDHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3592737-B1 | CROSS-LINKABLE ORGANOMETALLIC LIGHT EMITTING COMPLEXES | LOMOX LTD (GB) | 2022-12-21 | — | — | EP | claimed |
| US-11316118-B2 | Dibenzo[d,B]silole-based reactive mesogens | LOMOX LIMITED (GB) | 2022-04-26 | — | — | US | claimed |
| EP-3523313-B1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LTD (GB) | 2021-05-05 | — | — | EP | claimed |
| US-20190280223-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LIMITED (GB) | 2019-09-12 | — | — | US | claimed |
| EP-3523313-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | Lomox Limited (GB) | 2019-08-14 | — | — | EP | claimed |
| WO-2018162880-A1 | CROSS-LINKABLE ORGANOMETALLIC LIGHT EMITTING LIGANDS AND COMPLEXES | LOMOX LIMITED (GB) | 2018-09-13 | — | — | WO | claimed |
| WO-2018065786-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LIMITED (GB) | 2018-04-12 | — | — | WO | claimed |
| EP-1439590-A2 | Mono-, oligo- and poly-bis(thienyl) arylenes and their use as charge transport materials | MERCK PATENT GmbH (DE) | 2004-07-21 | — | — | EP | claimed |
| US-20040119049-A1 | Mono-, oligo- and poly-bis(thienyl) arylenes and their use as charge transport materials | MERCK PATENT GMBH (DE) | 2004-06-24 | — | — | US | claimed |
| CN-110382491-B | Crosslinkable organometallic luminescent ligands and complexes | 洛马克斯有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3592737-B1 | CROSS-LINKABLE ORGANOMETALLIC LIGHT EMITTING COMPLEXES | LOMOX LTD (GB) | 2022-12-21 | — | — | EP | disclosed |
| US-11316118-B2 | Dibenzo[d,B]silole-based reactive mesogens | LOMOX LIMITED (GB) | 2022-04-26 | — | — | US | disclosed |
| EP-3523313-B1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-10923662-B2 | Fluoroalkylfluorene derivatives | LOMOX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-1852922-A2 | Mono-, oligo- and poly-bis(thienyl)arylenes and their use as charge transport materials | Merck Patent GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| US-20050119491-A1 | 2, 7-Substituted carbazoles and oligomers, polymers and co-polymers thereof | SHEFFIELD, THE UNIVERSITY OF (GB) | 2005-06-02 | — | — | US | disclosed |
| EP-1453802-A1 | 2, 7 - SUBSTITUTED CARBAZOLES AND OLIGOMERS, POLYMERS AND CO-POLYMERS THEREOF | THE UNIVERSITY OF SHEFFIELD (GB) | 2004-09-08 | — | — | EP | disclosed |
| EP-1439590-A2 | Mono-, oligo- and poly-bis(thienyl) arylenes and their use as charge transport materials | MERCK PATENT GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20040119049-A1 | Mono-, oligo- and poly-bis(thienyl) arylenes and their use as charge transport materials | MERCK PATENT GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| WO-2003050086-A1 | 2, 7 - SUBSTITUTED CARBAZOLES AND OLIGOMERS, POLYMERS AND CO-POLYMERS THEREOF | THE UNIVERSITY OF SHEFFIELD (GB) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190280223-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | CCNB1, CCNE2, UBE2G2 | CYP3A4 850/4885GAA 4547/4885NPSR1 2641/4885 |
| US-11316118-B2 | Dibenzo[d,B]silole-based reactive mesogens | CCNB1, CCNE2, UBE2G2 | CYP3A4 850/4885GAA 4547/4885NPSR1 2641/4885 |
| US-10923662-B2 | Fluoroalkylfluorene derivatives | FLNB, AFF2, EFHD2 | CYP3A4 953/4885GAA 4277/4885NPSR1 2745/4885 |
| US-20050119491-A1 | 2, 7-Substituted carbazoles and oligomers, polymers and co-polymers thereof | CBR3, OR10J3, ORC3 | CYP3A4 1219/4885GAA 4812/4885NPSR1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.